Key result
A Deep Mutational Scan of the SCN5A voltage sensor using a triple drug assay successfully identified 40 putative gain-of-function and 33 putative loss-of-function variants.
Why the study?
Ion channel gene variants have classically been evaluated using low-throughput patch clamping, lacking high-throughput functional assessment.
Answers are grounded in this paper and cite their sources.
Deep Mutational Scanning provides a high-throughput, accurate in vitro method to simultaneously assess the functional impact of thousands of SCN5A variants, facilitating the identification of deleterious mutations in cardiac ion channel genes.
Variants in ion channel genes have classically been studied in low-throughput by patch clamping. Deep Mutational Scanning (DMS) is a complementary approach that can simultaneously assess function of thousands of variants. We have developed and validated a method to perform a DMS of variants in SCN5A , which encodes the major voltage-gated sodium channel in the heart. We created a library of nearly all possible variants in a 36 base region of SCN5A in the S4 voltage sensor of domain IV and stably integrated the library into HEK293T cells. In preliminary experiments, challenge with three drugs (veratridine, brevetoxin, and ouabain) could discriminate wildtype channels from gain and loss of function pathogenic variants. High-throughput sequencing of the pre- and post-drug challenge pools was used to count the prevalence of each variant and identify variants with abnormal function. The DMS scores identified 40 putative gain of function and 33 putative loss of function variants. For 8/9 variants, patch clamping data was consistent with the scores. These experiments demonstrate the accuracy of a high-throughput in vitro scan of SCN5A variant function, which can be used to identify deleterious variants in SCN5A and other ion channel genes.
No takes yet. Share an insight, caveat, or question.
Glazer et al. (2019) studied SCN5A variants (Brugada Syndrome, Long QT Syndrome). Deep Mutational Scan using triple drug assay (veratridine, brevetoxin, ouabain) vs. Wildtype SCN5A was evaluated on Identification of gain and loss of function variants based on cell survival. A Deep Mutational Scan of the SCN5A voltage sensor using a triple drug assay successfully identified 40 putative gain-of-function and 33 putative loss-of-function variants.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: